Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Open access
Burmester, Gerd R, Buttgereit, Frank, Bernasconi, Corrado, Álvaro-Gracia, Jose M, Castro, Nidia, Dougados, Maxime, Gabay, Cem, van Laar, Jacob M, Nebesky, Jan Michael, Pethoe-Schramm, Attila, Salvarani, Carlo, Donath, Marc Y, John, Markus R, Constantin, Arnaud, Gottenberg, Jacques Eric, Loiseau-Peres, Sylvie, Nguyen, Minh, Schaeverbeke, Thierry, Alten, Rieke H.-E., Amberger, Christopher, Biewer, Werner A., Boche, Konrad, Burmester, Gerd Ruediger, Engel, Andreas, Feuchtenberger, Martin, Fleck, Martin, Gauler, Georg, Heilig, Bernhard, Höhle, Maria, Iking-Konert, Christof, Kästner, Peter, Kofler, David, Krueger, Klaus, Kühne, Cornelia, Kurthen, Reiner, Schulze-Koops, Hendrik, Schwenke, Holger, Sieburg, Maren, Specker, Christof, Tony, Hans-Peter, Wassenberg, Siegfried, Wendler, Jörg, Caporali, Roberto, Epis, Oscar, Matucci-Cerinic, Marco, Salvarani, Carlo, Dubikov, Alexander, Kamalova, Rimma, Korolev, Maxim, I. Mazurov, Vadim, Puntus, Ekaterina, Damjanov, Nemanja, Ilic, Tatjana, Lazarevic, Milijanka, Milenkovic, Sasa, Petronijevic, Milan, Gabay, Cem, Bouajina, Elyes, Elleuch, Mohamed · 2020 · The Lancet

Abstract

Background Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised controlled trials to guide tapering of oral glucocorticoids is scarce. We investigated a scheme for tapering oral glucocorticoids compared with continuing low-dose oral glucocorticoids in patients with rheumatoid arthritis.Methods The Steroid EliMination In Rheumatoid Arthritis (SEMIRA) trial was a double-blind, multicentre, two parallel-arm, randomised controlled trial done at 39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia). Adult patients with rheumatoid arthritis receiving tocilizumab and glucocorticoids 5-15 mg per day for 24 weeks or more were eligible for inclusion if they had received prednisone 5 mg per day for 4 weeks or more and had stable low disease activaity, confirmed by a Disease Activity Score for 28 joints-erythrocyte sedimentation rate (DAS28-ESR) of 3·2 or less 4-6 weeks before and on the day of randomisation. Patients were randomly assigned 1:1 to either continue masked prednisone 5 mg per day for 24 weeks or to taper masked prednisone reaching 0 mg per day at week 16. All patients received tocilizumab (162 mg subcutaneously every week or 8 mg/kg intravenously every 4 weeks) with or without csDMARDs maintained at stable doses during the entire 24-week study. The primary outcome was the difference in mean DAS28-ESR change from baseline to week 24, with a difference of more than 0·6 defined as clinically relevant between the continued-prednisone group and the tapered-prednisone group. The trial is registered with ClinicalTrials.gov, NCT02573012.Findings Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77%] women and 59 [23%] men) were recruited onto the trial. In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08 (-0·27 to 0·12) with continued prednisone (difference 0·61 [0·35-0·88]; p<0·0001), favouring continuing prednisone 5 mg per day for 24 weeks. Treatment was regarded as successful (defined as low disease activity at week 24, plus absence of rheumatoid arthritis flare for 24 weeks and no confirmed adrenal insufficiency) in 99 (77%) patients in the continued-prednisone group versus 85 (65%) patients in the tapered-prednisone group (relative risk 0·83; 95% CI 0·71-0·97). Serious adverse events occurred in seven (5%) patients in the tapered-prednisone group and four (3%) patients in the continued-prednisone group; no patients had symptomatic adrenal insufficiency.Interpretation In patients who achieved low disease activity with tocilizumab and at least 24 weeks of glucocorticoid treatment, continuing glucocorticoids at 5 mg per day for 24 weeks provided safe and better disease control than tapering glucocorticoids, although two-thirds of patients were able to safely taper their glucocorticoid dose.Funding F Hoffmann-La Roche.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)30636-x

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 38 · Cited by 128

Metadata

Authors
Burmester, G. R., Buttgereit, F., Bernasconi, C., Álvaro-Gracia, J. M., Castro, N., Dougados, M., Gabay, C., van Laar, J. M., Nebesky, J. M., Pethoe-Schramm, A., Salvarani, C., Donath, M. Y., John, M. R., Constantin, A., Gottenberg, J. E., Loiseau-Peres, S., Nguyen, M., Schaeverbeke, T., Alten, R. H.-E., Amberger, C., Biewer, W. A., Boche, K., Burmester, G. R., Engel, A., Feuchtenberger, M., Fleck, M., Gauler, G., Heilig, B., Höhle, M., Iking-Konert, C., Kästner, P., Kofler, D., Krueger, K., Kühne, C., Kurthen, R., Schulze-Koops, H., Schwenke, H., Sieburg, M., Specker, C., Tony, H.-P., Wassenberg, S., Wendler, J., Caporali, R., Epis, O., Matucci-Cerinic, M., Salvarani, C., Dubikov, A., Kamalova, R., Korolev, M., I. Mazurov, V., Puntus, E., Damjanov, N., Ilic, T., Lazarevic, M., Milenkovic, S., Petronijevic, M., Gabay, C., Bouajina, E., & Elleuch, M.
Affiliations
  • Humboldt-Universität zu Berlin (DE)
  • F. Hoffmann-La Roche AG (CH)
  • Université Paris Descartes (FR)
  • University Hospital of Basel (CH)
Corresponding author
Burmester, Gerd R
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-07
Volume
396
Issue
10246
Pages
267-276
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3044002186
Cited by
128
References
38
Citations by year
2026: 11 · 2025: 10 · 2024: 26 · 2023: 28 · 2022: 23 · 2021: 20 · 2020: 10
FWCI
15.24
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion)
  • HAL (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
F. Hoffmann-La Roche
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
rheumatoid arthritis, glucocorticoid tapering, prednisone, low-dose glucocorticoids, tocilizumab, disease activity, remission, DAS28-ESR, csDMARDs, steroid-sparing therapy, glucocorticoid adverse effects, treatment discontinuation, disease flares
MeSH terms
Administration, Oral, Adult, Aged, Arthritis, Rheumatoid, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, France, Germany, Glucocorticoids, Humans, Injections, Subcutaneous, Italy, Male, Middle Aged, Prednisone, Remission Induction, Russia, Tunisia, Outcome Assessment, Health Care, Serbia, Antibodies, Monoclonal, Humanized, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30636-x
The paper
Burmester, G. R., Buttgereit, F., Bernasconi, C., Álvaro-Gracia, J. M., Castro, N., Dougados, M., Gabay, C., van Laar, J. M., Nebesky, J. M., Pethoe-Schramm, A., Salvarani, C., Donath, M. Y., John, M. R., Constantin, A., Gottenberg, J. E., Loiseau-Peres, S., Nguyen, M., Schaeverbeke, T., Alten, R. H.-E., . . . Elleuch, M. (2020). Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)30636-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.